drugset

drugset / Trial / NCT00216502

A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

NCT00216502 ↗

Phase 3 Completed 254 enrolled Janssen-Cilag S.p.A.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the long-term efficacy and safety of galantamine in patients with Alzheimer's disease.

Timeline

Start: 2001-08
Primary completion: —
Completion: 2005-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Galantamine	Small molecule	8 mg	Oral

Indications